Last $5.14 USD
Change Today +0.14 / 2.80%
Volume 9.5K
PDII On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

pdi inc (PDII) Snapshot

Open
$5.01
Previous Close
$5.00
Day High
$5.28
Day Low
$4.89
52 Week High
01/6/14 - $6.25
52 Week Low
05/13/13 - $3.82
Market Cap
79.0M
Average Volume 10 Days
14.2K
EPS TTM
$-0.31
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PDI INC (PDII)

pdi inc (PDII) Related Bloomberg News

View More Bloomberg News

pdi inc (PDII) Related Businessweek News

No Related Businessweek News Found

pdi inc (PDII) Details

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, and healthcare companies in the United States. The company’s services offer customers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It operates in three segments: Sales Services, Marketing Services, and Product Commercialization Services. The Sales Services segment focuses primarily on product detailing, which includes a sales representative meeting face-to-face with targeted physicians and other healthcare decision makers to provide a technical review of the product being promoted and deliver marketing materials, including samples. It also offers a portfolio of sales services consisting of talent acquisition services, short-term teams, and vacancy coverage services. The Marketing Services segment is involved in the creation, design, and implementation of interactive digital communications programs to the healthcare community through the Internet, multimedia, tablet PCs, mobile devices, and dimensional direct mails, as well as DIAGRAM, a proprietary software to deliver digital selling solutions through interactive communications exchanges that accommodate the schedules of healthcare providers. This segment is also engaged in the creation of teledetailing programs executed through tele-representatives. The Product Commercialization Services segment provides product commercialization solutions, including product distribution, product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management to pharmaceutical, biotechnology, medical device, and diagnostics clients. PDI, Inc. has a strategic collaboration agreement with Transgenomic, Inc. The company was founded in 1987 and is headquartered in Parsippany, New Jersey.

706 Employees
Last Reported Date: 03/6/14
Founded in 1987

pdi inc (PDII) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $566.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $337.1K
President of Sales Services
Total Annual Compensation: $303.4K
Compensation as of Fiscal Year 2012.

pdi inc (PDII) Key Developments

PDI, Inc. Appoints Greg Richard as General Manager for Interpace Diagnostics Subsidiary

PDI, Inc. has hired Greg Richard as General Manager for its Interpace Diagnostics subsidiary. Richard will be responsible for evolving and driving the execution of PDI's molecular diagnostics growth strategy. Mr. Richard has more than 20 years of experience in sales, marketing and managed care with life science companies ranging from Fortune 500 to small, privately held organizations. He joins PDI from Strata Pathology Services, where he restructured and grew the anatomical pathology sales organization and worked to expand the company's geographic presence. He was previously Executive Vice President of Sales and Marketing at Signal Genetics Earlier in his career, Richard was Northeast Vice President of Sales for LabCorp. Mr. Richard will oversee Interpace Diagnostics' operations, business development, sales and marketing functions. His responsibilities include the identification and establishment of new molecular diagnostics commercialization partnerships and managed care strategy development, and he will be a member of PDI's Executive Committee.

PDI, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Earnings Guidance for the Year of 2014

PDI, Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported net revenues of $36.414 million against $35.632 million a year ago. Operating loss was $3.631 million against $23.939 million a year ago. Loss from continuing operations before income tax was $3.660 million against $23.952 million a year ago. Loss from continuing operations was $3.648 million or $0.25 per diluted share against $23.941 million or $1.64 per diluted share a year ago. Net loss was $3.666 million or $0.25 per diluted share against $23.796 million or $1.63 per diluted share a year ago. Adjusted operating loss was $3.631 million against adjusted operating income of $0.284 million a year ago. Adjusted LBITDA was $2.924 million against adjusted EBITDA of $1.099 million a year ago. For the year, the company reported net revenues of $150.842 million against $126.899 million a year ago. Operating loss was $4.277 million against $25.232 million a year ago. Loss from continuing operations before income tax was $4.336 million against $25.260 million a year ago. Loss from continuing operations was $4.516 million or $0.31 per diluted share against $25.468 million or $1.75 per diluted share a year ago. Net loss was $4.565 million or $0.31 per diluted share against $25.527 million or $1.75 per diluted share a year ago. Net cash used in operations was $3.512 million against $10.286 million a year ago. Adjusted operating loss was $4.277 million against $1.009 million a year ago. Adjusted LBITDA was $1.129 million against adjusted EBITDA of $2.816 million a year ago. The annual EBITDA decline was primarily due to strategic investments in core infrastructure, molecular diagnostics and PD One. In terms of 2014 outlook, which assumes a reasonable level of new business wins and no early termination of existing contracts, the company anticipates revenue in core business to be down slightly compared to 2013, as a result of fewer new opportunities being available and awarded in 2013. Gross profit dollars are projected to be approximately flat compared to 2013, as profit from higher margin offerings and continued improvements in cost of services offset much of the impact of lower revenue. Finally, full year 2014 adjusted EBITDA from the core business is projected to be slightly positive. This guidance excludes the impact of Interpace Diagnostic business.

PDI, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 04:30 PM

PDI, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 04:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Jeffrey E. Smith, Chief Financial Officer, Principal Accounting Officer, Executive Vice President of Finance and Treasurer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDII:US $5.14 USD +0.14

PDII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hi-Tech Pharmacal Co Inc $43.49 USD 0.00
View Industry Companies
 

Industry Analysis

PDII

Industry Average

Valuation PDII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDI INC, please visit www.pdi-inc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.